- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
Medical-device maker Misonix said it voluntarily contacted the Securities and Exchange Commission and the U.S. Department of Justice this week to inform them about potential violations of the Foreign Corrupt Practices Act. Jaclyn Jaeger reports.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
The DOJ has now closed its investigation into medical device company Misonix—about a month after the SEC closed its probe—without bringing enforcement actions. The FCPA investigation still resulted in some extensive anti-corruption compliance reforms.
The SEC has closed its FCPA investigation into medical device company Misonix and will not be recommending an enforcement action, the company announced.
Whether you’re a multinational telecommunications company looking to certify your anti-corruption program post-settlement, or a biochemical company victimized by a “rogue” employee, seeing the light at the end of the enforcement tunnel isn’t always easy.
